Padmanabh P. Bhatt sold $5.4M of SUPN
Sr. VP of IP, CSO at SUPERNUS PHARMACEUTICALS, INC.. 107,250 shares at an average of $50.24, traded Mar 16, 2026, filed Mar 18, 2026.
Score components
- +15RoleOfficer
- +25Trade size$5.4M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.3%, 3m -11.6%, 6m -16.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001539215-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +22,750 | $36.75 | $836k | 39,794 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +4,250 | $29.61 | $126k | 44,044 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +18,000 | $32.20 | $580k | 62,044 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +5,000 | $27.94 | $140k | 67,044 | Mar 18, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -34,114 | $50.18 | $1.7M | 32,930 | Mar 18, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -15,886 | $50.49 | $802k | 17,044 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Common Stock10b5-1 | +22,750 | $39.40 | $896k | 39,794 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Common Stock10b5-1 | +12,250 | $36.75 | $450k | 52,044 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Common Stock10b5-1 | +15,000 | $38.60 | $579k | 67,044 | Mar 18, 2026 |
| Mar 17, 2026 | SOpen-market sale Common Stock10b5-1 | -27,710 | $49.95 | $1.4M | 39,334 | Mar 18, 2026 |
| Mar 17, 2026 | SOpen-market sale Common Stock10b5-1 | -22,290 | $50.73 | $1.1M | 17,044 | Mar 18, 2026 |
| Mar 18, 2026 | MOption exercise Common Stock10b5-1 | +7,250 | $39.40 | $286k | 24,294 | Mar 18, 2026 |
| Mar 18, 2026 | SOpen-market sale Common Stock10b5-1 | -6,838 | $49.55 | $339k | 17,456 | Mar 18, 2026 |
| Mar 18, 2026 | SOpen-market sale Common Stock10b5-1 | -412 | $50.48 | $21k | 17,044 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -22,750 | $0.00 | $0 | 12,250 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -4,250 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -18,000 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 15,000 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -22,750 | $0.00 | $0 | 7,250 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -12,250 | $0.00 | $0 | 0 | Mar 18, 2026 |
| Mar 17, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 5,000 | Mar 18, 2026 |
| Mar 18, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -7,250 | $0.00 | $0 | 0 | Mar 18, 2026 |
Related signals
Other insiders at SUPERNUS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | SUPERNUS PHARMACEUTICALS, INC. | Frederick M. Hudson director | $272k 5,369 shares | -8% | |
| 45Moderate | SUPERNUS PHARMACEUTICALS, INC. | Jack A. Khattar President, CEO | $1.8M 35,000 shares | -4% | |
| 53Moderate | SUPERNUS PHARMACEUTICALS, INC. | William Todd Horich SVP, Commercial Operations | $484k 8,877 shares | -100% | |
| 24Weak | SUPERNUS PHARMACEUTICALS, INC. | Frank Mottola SVP, Chief Tech. Ops. Officer | $87k 1,623 shares | -8% | |
| 50Moderate | SUPERNUS PHARMACEUTICALS, INC. | Georges Gemayel director | $1.0M 18,787 shares | -49% | |
| 21Weak | SUPERNUS PHARMACEUTICALS, INC. | Bethany Sensenig director | $228k 4,475 shares | -100% | |
| 33Weak | SUPERNUS PHARMACEUTICALS, INC. | Frank Mottola SVP, Chief Tech. Ops. Officer | $1.0M 20,000 shares | -98% | |
| 13Weak | SUPERNUS PHARMACEUTICALS, INC. | Padmanabh P. Bhatt Sr. VP of IP, CSO | $32k 710 shares | -5% | |
| 23Weak | SUPERNUS PHARMACEUTICALS, INC. | Jack A. Khattar President, CEO | $3.0M 59,900 shares | -5% | |
| 33Weak | SUPERNUS PHARMACEUTICALS, INC. | Charles W Newhall III director | $1.3M 25,000 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.